160 related articles for article (PubMed ID: 30257318)
1. Synthetic human monoclonal antibody targets hIL1 receptor accessory protein chain with therapeutic potential in triple-negative breast cancer.
Zheng P; Zhang Y; Zhang B; Wang Y; Wang Y; Yang L
Biomed Pharmacother; 2018 Nov; 107():1064-1073. PubMed ID: 30257318
[TBL] [Abstract][Full Text] [Related]
2. Structure-based Development of Human Interleukin-1β-Specific Antibody That Simultaneously Inhibits Binding to Both IL-1RI and IL-1RAcP.
Kuo WC; Lee CC; Chang YW; Pang W; Chen HS; Hou SC; Lo SY; Yang AS; Wang AH
J Mol Biol; 2021 Feb; 433(4):166766. PubMed ID: 33359099
[TBL] [Abstract][Full Text] [Related]
3. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
Amoury M; Kolberg K; Pham AT; Hristodorov D; Mladenov R; Di Fiore S; Helfrich W; Kiessling F; Fischer R; Pardo A; Thepen T; Hussain AF; Nachreiner T; Barth S
Cancer Lett; 2016 Mar; 372(2):201-9. PubMed ID: 26806809
[TBL] [Abstract][Full Text] [Related]
4. A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein.
Amoury M; Mladenov R; Nachreiner T; Pham AT; Hristodorov D; Di Fiore S; Helfrich W; Pardo A; Fey G; Schwenkert M; Thepen T; Kiessling F; Hussain AF; Fischer R; Kolberg K; Barth S
Int J Cancer; 2016 Aug; 139(4):916-27. PubMed ID: 27037627
[TBL] [Abstract][Full Text] [Related]
5. Intercellular Adhesion Molecule-1 as Target for CAR-T-Cell Therapy of Triple-Negative Breast Cancer.
Wei H; Wang Z; Kuang Y; Wu Z; Zhao S; Zhang Z; Li H; Zheng M; Zhang N; Long C; Guo W; Nie C; Yang H; Tong A
Front Immunol; 2020; 11():573823. PubMed ID: 33072116
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies.
Ashraf Y; Mansouri H; Laurent-Matha V; Alcaraz LB; Roger P; Guiu S; Derocq D; Robin G; Michaud HA; Delpech H; Jarlier M; Pugnière M; Robert B; Puel A; Martin L; Landomiel F; Bourquard T; Achour O; Fruitier-Arnaudin I; Pichard A; Deshayes E; Turtoi A; Poupon A; Simony-Lafontaine J; Boissière-Michot F; Pirot N; Bernex F; Jacot W; du Manoir S; Theillet C; Pouget JP; Navarro-Teulon I; Bonnefoy N; Pèlegrin A; Chardès T; Martineau P; Liaudet-Coopman E
J Immunother Cancer; 2019 Feb; 7(1):29. PubMed ID: 30717773
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of the soluble form of the interleukin-1 receptor accessory protein as an inhibitor of interleukin-1 in collagen-induced arthritis.
Smeets RL; van de Loo FA; Joosten LA; Arntz OJ; Bennink MB; Loesberg WA; Dmitriev IP; Curiel DT; Martin MU; van den Berg WB
Arthritis Rheum; 2003 Oct; 48(10):2949-58. PubMed ID: 14558102
[TBL] [Abstract][Full Text] [Related]
8. Soluble interleukin-1 receptor accessory protein ameliorates collagen-induced arthritis by a different mode of action from that of interleukin-1 receptor antagonist.
Smeets RL; Joosten LA; Arntz OJ; Bennink MB; Takahashi N; Carlsen H; Martin MU; van den Berg WB; van de Loo FA
Arthritis Rheum; 2005 Jul; 52(7):2202-11. PubMed ID: 15986350
[TBL] [Abstract][Full Text] [Related]
9. Human hepatitis B viral e antigen interacts with cellular interleukin-1 receptor accessory protein and triggers interleukin-1 response.
Yang CY; Kuo TH; Ting LP
J Biol Chem; 2006 Nov; 281(45):34525-36. PubMed ID: 16973626
[TBL] [Abstract][Full Text] [Related]
10. Molecular Basis of Selective Cytokine Signaling Inhibition by Antibodies Targeting a Shared Receptor.
Fields JK; Kihn K; Birkedal GS; Klontz EH; Sjöström K; Günther S; Beadenkopf R; Forsberg G; Liberg D; Snyder GA; Deredge D; Sundberg EJ
Front Immunol; 2021; 12():779100. PubMed ID: 35003094
[TBL] [Abstract][Full Text] [Related]
11. Antibodies to domains II and III of the IL-1 receptor accessory protein inhibit IL-1 beta activity but not binding: regulation of IL-1 responses is via type I receptor, not the accessory protein.
Yoon DY; Dinarello CA
J Immunol; 1998 Apr; 160(7):3170-9. PubMed ID: 9531272
[TBL] [Abstract][Full Text] [Related]
12. Engagement of IL-1 receptor accessory protein (IL-1RAcP) with the monoclonal antibody AY19 provides co-activating signals and prolongs the CD2-induced proliferation of peripheral blood lymphocytes.
Mansur IG; Schiavon V; Giustiniani J; Bagot M; Bensussan A; Marie-Cardine A
Immunol Lett; 2011 Sep; 139(1-2):52-7. PubMed ID: 21600927
[TBL] [Abstract][Full Text] [Related]
13. IL-1 signaling cascade in liver cells and the involvement of a soluble form of the IL-1 receptor accessory protein.
Jensen LE; Muzio M; Mantovani A; Whitehead AS
J Immunol; 2000 May; 164(10):5277-86. PubMed ID: 10799889
[TBL] [Abstract][Full Text] [Related]
14. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of anti-IL-1R accessory protein antibodies on IL-1alpha or IL-1beta-induced production of PGE(2) and IL-6 from 3T3-L1 cells.
Yoon DY; Dinarello CA
J Biochem Mol Biol; 2007 Jul; 40(4):562-70. PubMed ID: 17669273
[TBL] [Abstract][Full Text] [Related]
16. Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kappaB and MAPKs.
Towne JE; Garka KE; Renshaw BR; Virca GD; Sims JE
J Biol Chem; 2004 Apr; 279(14):13677-88. PubMed ID: 14734551
[TBL] [Abstract][Full Text] [Related]
17. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
[TBL] [Abstract][Full Text] [Related]
18. A combination of in vitro techniques for efficient discovery of functional monoclonal antibodies against human CXC chemokine receptor-2 (CXCR2).
Boshuizen RS; Marsden C; Turkstra J; Rossant CJ; Slootstra J; Copley C; Schwamborn K
MAbs; 2014; 6(6):1415-24. PubMed ID: 25484047
[TBL] [Abstract][Full Text] [Related]
19. Antiproliferative and apoptotic effects of a specific anti-insulin-like growth factor I receptor single chain antibody on breast cancer cells.
Motallebnezhad M; Younesi V; Aghebati-Maleki L; Nickho H; Safarzadeh E; Ahmadi M; Movassaghpour AA; Hosseini A; Yousefi M
Tumour Biol; 2016 Nov; 37(11):14841-14850. PubMed ID: 27639384
[TBL] [Abstract][Full Text] [Related]
20. RP215 single chain fragment variable and single domain recombinant antibodies induce cell cycle arrest at G0/G1 phase in breast cancer.
Yu F; Wang Y; Xiao Y; He Y; Luo C; Duan D; Li C; Xu S; Xiang T
Mol Immunol; 2014 May; 59(1):100-9. PubMed ID: 24534066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
